Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASKB 589

Next Previous
Drug Profile

ASKB 589

Alternative Names: ASKB-589

Latest Information Update: 02 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AskGene Pharma; Jiangsu Aosaikang Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastric cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 25 Jan 2024 Phase-III clinical trials in Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in China (IV) (NCT06206733)
  • 18 Jan 2024 Efficacy, pharmacokinetics and adverse events data from a phase-I/II clinical trials in Gastric cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 16 Jan 2024 AskGene Pharma plans a phase III trial for Gastric cancer (Late-stage disease, Inoperable/Unresectable, Recurrent, Metastatic disease, First-line therapy, Combination therapy) in China in January 2024 (IV, infusion) (NCT06206733)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top